ClinicalTrials.gg
RecruitingNCT06815666Updated Mar 4, 2026

BAL Fluid Biomarkers in Sarcoma

A Phase 2 interventional study of Bronchoscopy & Metastasectomy in Soft Tissue Sarcoma (STS), Bronchoalveolar Lavage (BAL) and Bronchoalveolar Lavage Fluid, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by University Health Network, Toronto · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Sarcoma by University Health Network, Toronto — 6 open to participants now, 7 under way, none of them phase 3. Sarcoma · University Health Network, Toronto.

Planned enrollment
3rd of 16
70 · median 33
Started
2025
with 1 other
Phase 2
6 of 18
3 open now
Registered
16th of 18
by date

Among the 18 studies in Sarcoma by University Health Network, Toronto, this one is the 3rd largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2025, is one of 6 in phase 2, and was the 16th registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

6 of the 18 studies in Sarcoma by University Health Network, Toronto are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Sarcoma by University Health Network, Toronto, or all of them as a file.
02

Study summary

This is a single-centre, Phase II, prospective study designed to assess BALF and TA-derived biomarkers in relation to metastatic burden in STS patients. BALF and TA samples will be collected during routine bronchoscopy performed as part of standard care at Toronto General Hospital (TGH). Additionally, tissue samples of lung metastases and adjacent normal lung will be collected and used to correlate the identified biomarkers.

03

Conditions studied

  • Soft Tissue Sarcoma (STS)
  • Bronchoalveolar Lavage (BAL)
  • Bronchoalveolar Lavage Fluid

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Ability to understand and willingness to sign a written document
  3. Diagnosed with soft tissue sarcoma
  4. Undergoing resection of lung lesion as part of standard care

Exclusion criteria

Exclusion Criteria:

1. History of another invasive , except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for ≥ 2 years

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Routine Bronchoscopy & SOC Metastasectomy

    BALF and TA will be collected during routine bronchoscopy, and resected lung metastases and adjacent normal tissue will be collected during standard of care metastasectomy

    Procedure: Bronchoscopy & Metastasectomy

Interventions

  • ProcedureBronchoscopy & Metastasectomy

    Routine bronchoscopy and standard of care metastasectomy

06

What researchers measure

Primary outcomes

  1. Identification of NET-related inflammatory biomarkers using BALF and TA diagnostic tools

    Bronchoalveolar lavage fluid (BALF) is a diagnostic tool used to sample cells and soluble substances from the lower respiratory tract. BALF allows for the examination of local immune responses and the identification of inflammatory markers. In the context of metastatic soft-tissue sarcoma, analyzing BALF can provide valuable insights into the presence and role of neutrophil extracellular traps (NETs) and other inflammatory factors within the lungs. On the other hand, tracheal aspirates (TA) can be more easily obtained from STS patients for biomarker identification.

    Time frame: 2 years

  2. Quantification of NET-related inflammatory biomarkers using BALF and TA diagnostic tool

    Bronchoalveolar lavage fluid (BALF) is a diagnostic tool used to sample cells and soluble substances from the lower respiratory tract. BALF allows for the examination of local immune responses and the identification of inflammatory markers. In the context of metastatic soft-tissue sarcoma, analyzing BALF can provide valuable insights into the presence and role of neutrophil extracellular traps (NETs) and other inflammatory factors within the lungs. On the other hand, tracheal aspirates (TA) can be more easily obtained from STS patients for biomarker identification.

    Time frame: 2 years

  3. Correlation of NET-related inflammatory markers using BALF and TA diagnostic tool with the extent of metastatic dissemination

    Bronchoalveolar lavage fluid (BALF) is a diagnostic tool used to sample cells and soluble substances from the lower respiratory tract. BALF allows for the examination of local immune responses and the identification of inflammatory markers. In the context of metastatic soft-tissue sarcoma, analyzing BALF can provide valuable insights into the presence and role of neutrophil extracellular traps (NETs) and other inflammatory factors within the lungs. On the other hand, tracheal aspirates (TA) can be more easily obtained from STS patients for biomarker identification.

    Time frame: 2 years

Secondary outcomes

  1. Analysis of NET-related inflammatory biomarkers using BALF and TA diagnostic tool

    Comparative analysis of NET-related inflammatory biomarkers in BALF and tracheal aspirates. Collected specimens will undergo comprehensive multi-omic analysis, encompassing proteomic, transcriptomic, and DNA sequencing methodologies to characterize the molecular landscape of disease progression associated with NETs.

    Time frame: 2 years

  2. Correlation between NET-related inflammatory biomarkers using BALF and TA diagnostic tool

    Correlation between the identified markers in BALF and tracheal aspirates with those found in resected pulmonary metastases and adjacent normal lung. The integration of these data will enable the identification of correlations between local and systemic disease features, uncovering potential biomarkers and pathways relevant to tumor progression and therapeutic targeting.

    Time frame: 2 years

  3. NET-related inflammatory biomarker differences for BALF and TA diagnostic tools

    Assessment of any differences in NET-related inflammatory biomarker profiles between patients with different metastatic burdens. For BALF and TAs, the supernatant will be analyzed to identify inflammatory biomarkers and NET-associated proteins, while cellular components will be subjected to RNA sequencing for transcriptomic profiling and DNA sequencing to explore genetic and epigenetic modifications.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Apr 2032, 86 months after the start.

Of 198 non-industry phase 2 interventional studies under Sarcoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 91. This study's planned 86 months is above that.

Counting every sponsor, half of 227 studies reached it within 66 months; a quarter within 43 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2025
First posted
Feb 7, 2025
StartActual
Jan 29, 2025
Primary completionEst.
Apr 1, 2032
CompletionEst.
Apr 1, 2032
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06815666
Responsible party
Sponsor
First posted
Feb 7, 2025
Start date
Jan 29, 2025
Primary completion
Apr 1, 2032 (estimated)
Completion
Apr 1, 2032 (estimated)
Last update
Mar 4, 2026

Study contacts

David Shultz
Contact
david.shultz@uhn.ca
416-946-4501 ext. 2121

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion